Public-Private Roles in the Pharmaceutical Sector - Implications for Equitable Access and Rational Drug Use - Health Economics and Drugs Series, No. 005
(1997; 115 pages) [French] [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoAuthors
Ver el documentoAcknowledgements
Ver el documentoAbbreviations and Acronyms
Ver el documentoExecutive summary
Abrir esta carpeta y ver su contenido1. Public and private roles in the pharmaceutical sector
Abrir esta carpeta y ver su contenido2. Pharmaceutical markets: structure and performance
Abrir esta carpeta y ver su contenido3. Essential state responsibilities
Abrir esta carpeta y ver su contenido4. The public-private mix in drug markets: a global picture1
Abrir esta carpeta y ver su contenido5. Market mechanisms in public drug supply
Abrir esta carpeta y ver su contenido6. Promoting public health needs through the private sector
Abrir esta carpeta y ver su contenido7. Pharmaceutical production and public-private roles
Cerrar esta carpeta8. Capacity-building and the process of change
Ver el documento8.1 The nature of capacity and capacity constraints
Ver el documento8.2 Approaches to enhancing capacity
Ver el documento8.3 The process of change
Ver el documento8.4 Summary points
Abrir esta carpeta y ver su contenido9. Managing public-private roles
Ver el documentoReferences
Ver el documentoGlossary
Ver el documentoBack Cover
 

8.2 Approaches to enhancing capacity

Training programmes, both basic education and continuing education, are the standard response to problems of capacity. But adequate capacity is unlikely to be developed by these methods alone. More innovative approaches are required:

• Many of the new skills required, such as negotiating skills, can be acquired only through experience. Organizations and individuals practising these skills, such as drug purchasing offices negotiating direct delivery or prime vendor systems, need the opportunity to reflect on and evaluate their experiences. International organizations may play a role in facilitating this.

• Capacity may be enhanced by increasing collaboration between the public and private sectors through, for example, the exchange of personnel between private firms and regulatory agencies and the use of private sector databases to help with regulatory efforts. To prevent conflict of interest, however, there need to be clear guidelines and structures for such exchanges.

• There are high fixed costs associated with many aspects of pharmaceutical regulation, and small countries will always find these difficult to bear. International collaboration may be a means to reduce the regulatory burden on individual countries. It could take the form of regional drug inspection agencies or mutual recognition agreements between drug inspection agencies.

• Legal, economic, planning and management skills in ministries of health need to be strengthened and augmented to manage new public-private roles. Traditional training programmes could contribute in this area.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013